Form 4: Theravance Biopharma CFO Executes Tax-Related Share Sale

CFO Aziz Sawaf disposed of 8,670 shares of Theravance Biopharma to satisfy tax obligations related to RSU vesting.

Summary

• Aziz Sawaf, SVP & Chief Financial Officer of Theravance Biopharma, Inc., reported the disposition of 8,670 ordinary shares.
• The transaction occurred on May 20, 2026, at a price of $16.55 per share.
• The shares were withheld by the issuer to satisfy tax withholding obligations resulting from the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 344,953 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine tax-related transaction rather than a strategic shift or discretionary insider trading.

Positives

• The transaction was a non-discretionary event related to tax obligations rather than an open-market sale, indicating continued alignment with company equity.

Negatives

• Reduction in the total number of shares held directly by the CFO.

Risks

• None identified; this is a routine administrative transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard corporate practice for executives receiving equity compensation and does not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices in the biotechnology sector where RSUs are common.
• The withholding mechanism is consistent with SEC reporting requirements for equity-based compensation plans.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-market tax settlement.

Key Dates

Keywords

Theravance Biopharma, TBPH, Insider Trading, Form 4, CFO, Equity Compensation